Navigation Links
DURECT Corporation Announces Fourth Quarter and Year End 2010 Financial Results
Date:3/2/2011

ndpoints, our potential failure to maintain our collaborative agreements with third parties or consummate new collaborations and DURECT's (and that of its third party collaborators where applicable) difficulty or failure to obtain approvals from regulatory agencies with respect to its development activities and products, or ability to design, enroll, conduct and complete clinical trials, complete the design, development, and manufacturing process development of the referenced product candidates, manufacture and commercialize the referenced product candidates, obtain marketplace acceptance of the referenced product candidates, avoid infringing patents held by other parties and secure and defend patents of our own, and manage and obtain capital to fund its growth, operations and expenses. Further information regarding these and other risks is included in DURECT's Form 10-Q on November 4, 2010 under the heading "Risk Factors."

DURECT CORPORATION STATEMENTS OF OPERATIONS DATA(in thousands, except per share amounts)(unaudited)Three months ended Year ended December 31, December 31, 201020092010 2009  (1)Collaborative research and development and other revenue

$  5,929$  2,802$  20,091$  12,347Product revenue, net

2,5672,07611,50012,113Total revenues

8,4964,87831,59124,460Operating expenses:Cost of revenues (2)

1,1778164,2755,311Research and development (2)

9,4479,26736,21434,801Selling, general and administrative (2)

4,0453,43214,93715,020Total operating expenses

14,66913,51555,42655,132Loss from operations

(6,173)(8,637)(23,835)(30,672)Other income (expense):Interest and other income

85853943420Interest and other expense

(1)(5)(6)(36)Net other income

85748937384Net loss

$ (5,316)$ (8,589)$ (22,898)$ (30,288)Net loss per share, basic and diluted

$   (0.06)$   (0.10)$
(0.26)$
(0.36)Shares used in computing basic and diluted net los
'/>"/>

SOURCE DURECT Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. DURECTs Collaboration With Alpharma Clears HSR Review and Is Effective
2. DURECT Corporation Announces Third Quarter 2008 Financial Results
3. DURECT Corporation Invites You to Join its Third Quarter 2010 Earnings Conference Call
4. Verenium Corporation to Present at Canaccord Adams 28th Annual Global Growth Conference
5. Pharmos Corporation Reports 2008 Second Quarter Results
6. China Bionanometer Industries Corporation Promotes New Product Beauty Look in China
7. Genaera Corporation Announces Second Quarter Financial Results
8. MannKind Corporation Reports Second Quarter Financial Results
9. [video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.nets 3-Minute Press Show
10. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
11. CEL-SCI CORPORATION Reports Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... 2015 Launched by the ... in December 2011, ,SARAH, - the French ... versus sorafenib in advanced hepatocellular carcinoma (HCC) has enrolled ... SARAH, a large French study of patients ... HCC) has completed patient enrolment, exceeding its 400-patient target, ...
(Date:3/3/2015)... March 3, 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: ... and molecular diagnostics that target the underlying mechanisms of ... seventh-month period ended December 31, 2014. Effective ... end from May 31 to December 31. As a ... today are for the quarter and the seven months ...
(Date:3/3/2015)... Experts and industry insiders from around ... the Alltech REBELation exploring innovation, inspiration and world-changing ideas ... its 31st year, Alltech’s annual international conference traditionally draws ... opportunity to join the REBELation at an extra discount ... EST, at which point the standard early registration rate ...
(Date:3/3/2015)... -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) announced ... Executive Officer of Neurocrine Biosciences, will be presenting at ... The live presentation takes place on Tuesday, March ... be webcast and may be accessed on the Company,s ... are encouraged to visit the website approximately 5 minutes ...
Breaking Biology Technology:Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 2Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 3Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 4Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 5Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 6Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 7Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 8Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 9Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 10Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 11Aptose Biosciences reports results for the quarter and seven months ended December 31, 2014 12World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 2World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 3World-renowned Leaders, Authors and Businesspeople Join the Alltech REBELation 4
... December 19, 2011 The " ... (2010 - 2020) " analyzes and studies ... such as North America, Europe, and Japan. ... on   Acute Myeloid Leukemia Therapeutics Market ...
... 19, 2011 Unigene Laboratories, Inc. (OTCBB: UGNE) ... announced that its management team has put key elements ... eliminating the inherited debt.  Unigene also reaffirmed that the ... into the second half of 2012, following a corporate ...
... New Report Added in ResearchMoz Reports Database  ... Logic Devices (PLD) and Application Specific Standard Product (ASSP) Dominate ... GBI Research . GBI Research,s report, ... (PLD) and Application Specific Standard Product (ASSP) Dominate with a ...
Cached Biology Technology:MarketsandMarkets: Acute Myeloid Leukemia Therapeutics Market in G8 Countries Worth $1.67 Billion by 2020 2MarketsandMarkets: Acute Myeloid Leukemia Therapeutics Market in G8 Countries Worth $1.67 Billion by 2020 3Unigene's 2011 Year in Review - Key Elements in Place to Address Debt in 2012 2Unigene's 2011 Year in Review - Key Elements in Place to Address Debt in 2012 3Unigene's 2011 Year in Review - Key Elements in Place to Address Debt in 2012 4Unigene's 2011 Year in Review - Key Elements in Place to Address Debt in 2012 5Unigene's 2011 Year in Review - Key Elements in Place to Address Debt in 2012 6Unigene's 2011 Year in Review - Key Elements in Place to Address Debt in 2012 7Unigene's 2011 Year in Review - Key Elements in Place to Address Debt in 2012 8ResearchMoz: Logic Integrated Circuit (IC) Market to 2020 - Programmable Logic Devices (PLD) and Application Specific Standard Product (ASSP) Dominate with a 78% Market Share 2ResearchMoz: Logic Integrated Circuit (IC) Market to 2020 - Programmable Logic Devices (PLD) and Application Specific Standard Product (ASSP) Dominate with a 78% Market Share 3ResearchMoz: Logic Integrated Circuit (IC) Market to 2020 - Programmable Logic Devices (PLD) and Application Specific Standard Product (ASSP) Dominate with a 78% Market Share 4
(Date:2/10/2015)... Feb. 10, 2015  Alere Inc. (NYSE: ALR), ... financial results for the quarter ended December 31, ... and President of Alere said, "We made substantial ... as the global leader in rapid diagnostics and ... Alere Health divestiture in early January enabled us ...
(Date:2/5/2015)... , Jan. 26, 2015   Epic Sciences , a ... today announced that Murali Prahalad , Ph.D., president and ... World Conference (PMWC) 2015: Silicon Valley, which is taking ... View, Calif. on January 26-28, 2015. ... of Age as Biomarkers." Last year, Epic Sciences was a ...
(Date:2/5/2015)... , Jan. 28, 2015 NXT-ID, Inc. ... the "Company"), a biometric authentication company focused on the ... the upcoming RedChip Global Online CEO Conference on January ... Gino Pereira , CEO of NXT-ID will ... lead product, the Wocket smart wallet and its full ...
Breaking Biology News(10 mins):Alere Inc. Announces Fourth Quarter 2014 Results 2Alere Inc. Announces Fourth Quarter 2014 Results 3Alere Inc. Announces Fourth Quarter 2014 Results 4Alere Inc. Announces Fourth Quarter 2014 Results 5Alere Inc. Announces Fourth Quarter 2014 Results 6Alere Inc. Announces Fourth Quarter 2014 Results 7Alere Inc. Announces Fourth Quarter 2014 Results 8Alere Inc. Announces Fourth Quarter 2014 Results 9Alere Inc. Announces Fourth Quarter 2014 Results 10Alere Inc. Announces Fourth Quarter 2014 Results 11Alere Inc. Announces Fourth Quarter 2014 Results 12Alere Inc. Announces Fourth Quarter 2014 Results 13Alere Inc. Announces Fourth Quarter 2014 Results 14Alere Inc. Announces Fourth Quarter 2014 Results 15Alere Inc. Announces Fourth Quarter 2014 Results 16Alere Inc. Announces Fourth Quarter 2014 Results 17Alere Inc. Announces Fourth Quarter 2014 Results 18Alere Inc. Announces Fourth Quarter 2014 Results 19Alere Inc. Announces Fourth Quarter 2014 Results 20Alere Inc. Announces Fourth Quarter 2014 Results 21Alere Inc. Announces Fourth Quarter 2014 Results 22Alere Inc. Announces Fourth Quarter 2014 Results 23Alere Inc. Announces Fourth Quarter 2014 Results 24Alere Inc. Announces Fourth Quarter 2014 Results 25Alere Inc. Announces Fourth Quarter 2014 Results 26Alere Inc. Announces Fourth Quarter 2014 Results 27Alere Inc. Announces Fourth Quarter 2014 Results 28Alere Inc. Announces Fourth Quarter 2014 Results 29Alere Inc. Announces Fourth Quarter 2014 Results 30Alere Inc. Announces Fourth Quarter 2014 Results 31Alere Inc. Announces Fourth Quarter 2014 Results 32Alere Inc. Announces Fourth Quarter 2014 Results 33Alere Inc. Announces Fourth Quarter 2014 Results 34Alere Inc. Announces Fourth Quarter 2014 Results 35Alere Inc. Announces Fourth Quarter 2014 Results 36
... Va., June 10 Stanley, Inc. (NYSE:,SXE), a ... the U.S. federal government, announced today that it ... Associates, Inc. (Oberon), an,engineering, intelligence operations and information ... $170 million in cash,subject to certain working capital ...
... detected subtle changes that may make the bowel more vulnerable ... the Food Standards Agency and the Biotechnology and Biological Sciences ... changes and delay or reverse the onset of cancer. ... role in the very earliest stages of colorectal cancer," says ...
... Monash University research into heavy metal contaminant levels in ... has revealed high mercury levels may be a contributing ... School of Biological Sciences have confirmed levels of mercury ... to cause negative health and mental effects and were ...
Cached Biology News:Stanley to Acquire Oberon Associates 2Stanley to Acquire Oberon Associates 3Stanley to Acquire Oberon Associates 4'Addicted' cells provide early cancer diagnosis 2Mercury contamination found in stranded Victorian dolphins 2
Canine Aortic Smooth Muscle Cells (CnAOSMC) (>500,000 cells)...
... Hot Start Taq Monoclonal ... before the onset of ... amplification and primer-dimer formation. ... raised, the antibody is ...
... Hex, Tet Cy3, Cy5, Texas Red, ... Hole Quenchers Molecular Beacons* ... 3 Dabcyl Dabcyl*Licensed from the ... labelled probes are purified either by HPLC ...
... Enterokinase (rEK) is a highly purified preparation ... a serine protease which recognizes the identical ... and has similar enzymatic activity (1). Novagen&'s ... purified to yield the highest activity available, ...
Biology Products: